Amazentis SA, EPFL Innovation Park, Bâtiment C, 1015 Lausanne, Switzerland.
Amazentis SA, EPFL Innovation Park, Bâtiment C, 1015 Lausanne, Switzerland.
Cell Rep Med. 2022 May 17;3(5):100633. doi: 10.1016/j.xcrm.2022.100633.
Targeting mitophagy to activate the recycling of faulty mitochondria during aging is a strategy to mitigate muscle decline. We present results from a randomized, placebo-controlled trial in middle-aged adults where we administer a postbiotic compound Urolithin A (Mitopure), a known mitophagy activator, at two doses for 4 months (NCT03464500). The data show significant improvements in muscle strength (∼12%) with intake of Urolithin A. We observe clinically meaningful improvements with Urolithin A on aerobic endurance (peak oxygen oxygen consumption [VO]) and physical performance (6 min walk test) but do not notice a significant improvement on peak power output (primary endpoint). Levels of plasma acylcarnitines and C-reactive proteins are significantly lower with Urolithin A, indicating higher mitochondrial efficiency and reduced inflammation. We also examine expression of proteins linked to mitophagy and mitochondrial metabolism in skeletal muscle and find a significant increase with Urolithin A administration. This study highlights the benefit of Urolithin A to improve muscle performance.
靶向线粒体自噬以激活衰老过程中受损线粒体的回收是减轻肌肉衰退的一种策略。我们报告了一项在中年成年人中进行的随机、安慰剂对照试验的结果，在该试验中，我们给予两种剂量的后生元化合物尿石素 A（Mitopure），一种已知的线粒体自噬激活剂，持续 4 个月（NCT03464500）。数据显示，摄入尿石素 A 可显著提高肌肉力量（约 12%）。我们观察到尿石素 A 对有氧耐力（峰值耗氧量[VO]）和身体表现（6 分钟步行测试）有临床意义的改善，但对峰值功率输出（主要终点）没有显著改善。尿石素 A 可显著降低血浆酰基辅酶 A 和 C 反应蛋白水平，表明线粒体效率更高，炎症减少。我们还检查了骨骼肌中线粒体自噬和线粒体代谢相关蛋白的表达，发现尿石素 A 给药后显著增加。这项研究强调了尿石素 A 改善肌肉性能的益处。
